Cempra (CEMP) announced on Tuesday that enrollment in the phase III SOLITAIRE-IV trial is complete, and the company expects data from the study in the fourth quarter of this year.
Given the similarities between SOLITAIRE-IV and -ORAL, which was complete in January of 2015, we can get a tighter bead on when the -IV results will be released by looking at the time between enrollment completion and top-line data from -ORAL earlier this year.
Already a Premium user? Sign In